

Resource Summary Report

Generated by T1D on Aug 2, 2026

MediBeacon

RRID:SCR_003987

Type: Tool

Proper Citation

MediBeacon (RRID:SCR_003987)

Resource Information

URL: <http://medibeacon.com/>

Proper Citation: MediBeacon (RRID:SCR_003987)

Description: A commercial optical diagnostic company focused on providing clinicians with critical information to improve patient care. The Optical Renal Function Monitor (ORFM) is their first product platform and is focused on real-time, easy to use, and cost-effective monitoring of kidney function. Their non-invasive monitoring technology works in a similar fashion to pulse oximetry by using a light sensor placed on the skin. After the sensor has been placed, a proprietary biocompatible tracer is administered. The system can then monitor the patient's real-time point-of-care kidney function. This information will allow for earlier detection of renal issues enabling clinicians to provide earlier, and hence more effective interventions. MediBeacon has created a research grade technique that is clinically applicable for real-time point-of-care Glomerular Filtration Rate measurement (mGFR). MediBeacon has invented a fluorescent tracer agent (MB-102) that is removed from the blood exclusively by the GFR mechanism of the kidneys. Together with their non-invasive detection device, this will deliver a real-time point-of-care measurement of GFR.

Abbreviations: MediBeacon

Synonyms: MediBeacon LLC

Resource Type: commercial organization

Keywords: kidney function, kidney, patient care, clinical, nephrology, glomerular filtration rate, medical device

Related Condition: Kidney disease

Resource Name: MediBeacon

Resource ID: SCR_003987

Alternate IDs: nlx_158398

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260801T190226+0000

Ratings and Alerts

No rating or validation information has been found for MediBeacon.

No alerts have been found for MediBeacon.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Zhang F, et al. (2025) An eCIRP inhibitor attenuates fibrosis and ferroptosis in ischemia and reperfusion induced chronic kidney disease. Molecular medicine (Cambridge, Mass.), 31(1), 11.

Wang Y, et al. (2025) Comparative analysis of hyperuricemia induction methods and probiotic interventions in mice. Current research in microbial sciences, 9, 100422.

Pushpakumar S, et al. (2025) Diallyl Trisulfide Attenuates Ischemia-Reperfusion-Induced ER Stress and Kidney Dysfunction in Aged Female Mice. Cells, 14(6).

Ramalingam H, et al. (2025) An RNA transmethylation pathway governs kidney nephrogenic potential. Nature communications, 16(1), 4930.

Kaseda S, et al. (2025) Efficacy of Nrf2 activation in a proteinuric Alport syndrome mouse model. Life science alliance, 8(8).

Ramasamy C, et al. (2024) Podocyte cell-specific Npr1 is required for blood pressure and renal homeostasis in male and female mice: role of sex-specific differences. Physiological genomics, 56(10), 672.

Gyarmati G, et al. (2024) Neuronally differentiated macula densa cells regulate tissue remodeling and regeneration in the kidney. The Journal of clinical investigation, 134(11).

Lima Posada I, et al. (2024) Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease. Journal of the American Heart Association, 13(12), e032971.

Martos-Guillami N, et al. (2024) SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice. *Frontiers in pharmacology*, 15, 1415879.

Lin J, et al. (2024) Injectable Genetic Engineering Hydrogel for Promoting Spatial Tolerance of Transplanted Kidney in Situ. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 11(48), e2408631.

Fanous MS, et al. (2024) EARLY FLUID PLUS NOREPINEPHRINE RESUSCITATION DIMINISHES KIDNEY HYPOPERFUSION AND INFLAMMATION IN SEPTIC NEWBORN PIGS. *Shock (Augusta, Ga.)*, 61(6), 885.

Becerra Calderon A, et al. (2024) Angiotensin II Directly Increases Endothelial Calcium and Nitric Oxide in Kidney and Brain Microvessels In Vivo With Reduced Efficacy in Hypertension. *Journal of the American Heart Association*, 13(10), e033998.

Siddiqui SH, et al. (2024) Impact of inhibition of the renin-angiotensin system on early cardiac and renal abnormalities in Sprague Dawley rats fed short-term high fructose plus high salt diet. *Frontiers in nutrition*, 11, 1436958.

Mallet J, et al. (2023) A model of hemodialysis after acute kidney injury in rats. *Intensive care medicine experimental*, 11(1), 97.

Huang TS, et al. (2023) Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice. *Nature communications*, 14(1), 390.

Faivre A, et al. (2023) Evolution of hypoxia and hypoxia-inducible factor asparaginyl hydroxylase (FIH) regulation in chronic kidney disease. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*.

Kunke M, et al. (2023) Targeted deletion of von-Hippel-Lindau in the proximal tubule conditions the kidney against early diabetic kidney disease. *Cell death & disease*, 14(8), 562.

Calvert ND, et al. (2023) Direct mapping of kidney function by DCE-MRI urography using a tetrazinanone organic radical contrast agent. *Nature communications*, 14(1), 3965.

Jang SM, et al. (2023) Adsorption and Clearance of the Novel Fluorescent Tracer Agent MB-102 During Continuous Renal Replacement Therapy: In Vitro Results. *ASAIO journal (American Society for Artificial Internal Organs : 1992)*, 69(7), 702.

Kidokoro K, et al. (2023) Insights into the Regulation of GFR by the Keap1-Nrf2 Pathway. *Kidney360*, 4(10), 1454.